Navigation Links
SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
Date:9/10/2007

l trial for CS and the only intranasal antifungal that has been submitted to the FDA as an Investigative New Drug (IND). The initial study population is with patients that have severe CS who have undergone sinus surgery, but who are struggling with recurrent CS.

Despite the fact that there are over 60 million patients in the U.S. and EU that have CS, and that CS is by far the most common chronic respiratory disease with a commercial market approximately twice the size of asthma, there is currently no approved prescription pharmaceutical available for treatment of the disease. If approved, SinuNase will be the first therapy available to treat sufferers of CS.

Accentia Biopharmaceuticals is commercializing SinuTest for the confirmation of CS. Investigators at Mayo discovered that a ubiquitous, normally innocuous mold, Alternaria, colonizes in the mucus of the nose and sinus of virtually everybody. However, it was found that in patients with CS, this non-invasive mold elicits an eosinophilic inflammatory response characterized by the release of eMBP in the mucus, which then damages the mucosal epithelial lining of the nose and sinuses, leading to the inflammatory mucosal changes characteristic of CS. The SinuTest diagnostic uses a small sample of mucus from the patient's nose and tests for eMBP, which is uniquely detectable in the nasal mucin of patients with CS.


'/>"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
Source:Eurekalert

Page: 1 2

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Worlds largest rainforest drying experiment completes first phase
3. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
4. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
5. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. NIH announces phase III clinical trial of creatine for Parkinsons disease
8. Farm kids almost twice as likely to die from injury as children overall
9. Chronic pain up almost 40 percent among US workers in past decade
10. Hunger in America rises by 43 percent over last five years
11. Method slashes quantum dot costs by 80 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... to take a healthy salad up a level by ... cancer in leafy greens. , "In the long run, ... eating the salad or making a pill from the ... engineering at Case Western Reserve School of Medicine and ... breast cancer organization is funding the research with a ...
(Date:9/30/2014)... each year, but its deep-blue waters host the ... alien species, including fish, crustaceans, and algae are ... In the open-access journal Frontiers in Marine ... data from a new information system developed by ... of alien species has changed the native biodiversity ...
(Date:9/30/2014)... Ocean Health Index rates the Earth,s oceans at ... addition, for the first time, the report assessed ... national jurisdiction (high-seas areas) all critical regions ... providing sustainable food sources. , In the third ... by scientists from UC Santa Barbara,s National Center ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Biodiversity in the Mediterranean is threatened by alien species 2Rating the planet's oceans 2Rating the planet's oceans 3
... new map of the potato genome that may lead ... help feed the world,s hungry. By sequencing and ... consortium has, for the first time, tied specific potato ... and development of potatoes may enable scientists and breeders ...
... Institute, one of the National Institutes of Health, has ... of Medicine each approximately $2.3 million a year for ... Glycosciences. Gerald Hart, Ph.D., director of biological chemistry and ... will lead these independent efforts to better understand the ...
... TORONTO, Ont., July 12, 2001--Eating nuts every day could ... according to new research from St. Michael,s Hospital and ... online by the journal Diabetes Care , a ... of Toronto Department of Nutritional Sciences; St. Michael,s Hospital ...
Cached Biology News:Johns Hopkins researchers awarded $32 million 2A 'nutty' solution to type 2 diabetes management 2
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
(Date:9/30/2014)... 2014 Proove Biosciences , the ... to announce a new genetic test built upon research ... Perception Test will provide physicians with an objective ... tolerance levels are stratified between individuals. With this new ... person has a genetic predisposition that will affect their ...
(Date:9/30/2014)... Fast, semi-automatic creation of ... documents ChemAxon , a leader ... for life science research, launches ChemCurator, an application ... from documents. Markush structures are essential ... and understanding Markush structures is a difficult and ...
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... second can make the difference between life and death, ... sensors" that allow for faster response times from military ... NC State that will help ensure those sensors will ... Afghanistan or elsewhere. "We,ve taken a sensor material ...
... ... of 2007 and to enhance patient safety with complete part traceability, can now use ... coding, scan and software tracking of each part and batch, including all leak test, ... ...
... the pleasantness of novel odors, just like a human ... notion that smell is completely personal and culture-specific. The ... Wolfson Medical Center, argue that the perception of an ... and it is only within specific contexts that personal ...
Cached Biology Technology:InterTech Development Company UDI System Announced 2Odor pleasantness shown to be partly hard-wired 2Odor pleasantness shown to be partly hard-wired 3
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [Flt-1/EWC] to VEGF Receptor 1 ( Abpromise for all tested applications). entrezGeneID: 2321 SwissProtID: P17948...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: